ChemoCentryx, Inc. (CCXI) Announces Completion of Target Enrollment of CCX140 Phase II Clinical Trial in Diabetic Nephropathy
6/19/2013 9:25:34 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MOUNTAIN VIEW, Calif., June 19, 2013 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced that it has completed the target enrollment of 270 patients in a Phase II clinical trial in diabetic nephropathy with CCX140, an inhibitor of the chemokine receptor known as CCR2 and the Company's lead wholly owned drug candidate. Enrollment will be closed by June 30, 2013, at which time ChemoCentryx expects total enrollment to exceed 300 patients in the randomized, double-blind, placebo-controlled study.
Help employers find you! Check out all the jobs and post your resume.
comments powered by